• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

宫内激素系统的非避孕健康益处。

Non-contraceptive health benefits of intrauterine hormonal systems.

机构信息

Department of Obstetrics, Gynaecology and Neonatology, Queen Elizabeth II Research Institute for Mothers and Infants, University of Sydney, NSW 2006, Australia.

出版信息

Contraception. 2010 Nov;82(5):396-403. doi: 10.1016/j.contraception.2010.05.005.

DOI:10.1016/j.contraception.2010.05.005
PMID:20933112
Abstract

Non-contraceptive health benefits are now recognized as an important aspect of the overall impact of all hormonal contraceptives. The levonorgestrel-releasing intrauterine systems (LNG IUS) are particularly effective at producing a number of health benefits for women using the LNG IUS as a contraceptive (reduced menstrual bleeding; reduced dysmenorrhea and the potential for prevention of a number of gynecological conditions in the longer term, such as iron-deficiency anemia, endometrial hyperplasia, uterine fibroids, acute episodes of pelvic inflammatory disease, endometriosis and perhaps others). The LNG IUS also has the potential to specifically treat a range of pre-existing gynecological conditions such as heavy menstrual bleeding due to a wide range of underlying causes, endometrial hyperplasia, uterine fibroids, adenomyosis, and endometriosis. These health benefits should be recognized as a key component in the decision-making process for individual women in choosing a specific type of hormonal or other contraceptive. Investment in research into the very substantial health benefits of hormonal contraceptives, such as the LNG IUS, has generally been ignored in comparison with the massive investment into understanding the often subtle or rare complications of hormonal contraceptive use. Both are important, but there is a real need to define more accurately those women who will benefit most from these health benefits.

摘要

非避孕健康益处现已被视为所有激素避孕方法整体影响的一个重要方面。左炔诺孕酮宫内节育系统(LNG IUS)在为使用 LNG IUS 作为避孕方法的女性带来多种健康益处方面特别有效(减少月经出血;减轻痛经,并且从长期来看可能预防一些妇科疾病,如缺铁性贫血、子宫内膜增生、子宫肌瘤、盆腔炎急性发作、子宫内膜异位症等)。LNG IUS 还有可能专门治疗一系列现有的妇科疾病,如由多种潜在病因引起的月经过多、子宫内膜增生、子宫肌瘤、子宫腺肌病和子宫内膜异位症。这些健康益处应该被视为女性在选择特定类型的激素或其他避孕方法时做出决策的关键因素。与大量投资于了解激素避孕使用中常见或罕见的副作用相比,对激素避孕药具(如 LNG IUS)的大量健康益处的研究投资通常被忽视。这两者都很重要,但确实需要更准确地确定那些最能从这些健康益处中受益的女性。

相似文献

1
Non-contraceptive health benefits of intrauterine hormonal systems.宫内激素系统的非避孕健康益处。
Contraception. 2010 Nov;82(5):396-403. doi: 10.1016/j.contraception.2010.05.005.
2
Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception.曼月乐(左炔诺孕酮宫内节育系统):一种成功的新型避孕药物递送选择。
Adv Drug Deliv Rev. 2009 Aug 10;61(10):808-12. doi: 10.1016/j.addr.2009.04.022. Epub 2009 May 13.
3
Added health benefits of the levonorgestrel contraceptive intrauterine system and other hormonal contraceptive delivery systems.增加了左炔诺孕酮避孕宫内节育系统和其他激素避孕输送系统的健康益处。
Contraception. 2013 Mar;87(3):273-9. doi: 10.1016/j.contraception.2012.08.039. Epub 2012 Oct 4.
4
The Femilis LNG-IUS: contraceptive performance-an interim analysis.费米利斯左炔诺孕酮宫内缓释系统:避孕效果——一项中期分析。
Eur J Contracept Reprod Health Care. 2009 Apr;14(2):103-10. doi: 10.1080/13625180802706059.
5
Selection and performance of the levonorgestrel-releasing intrauterine system.左炔诺孕酮宫内节育系统的选择与性能
Acta Obstet Gynecol Scand Suppl. 1997;164:69-74.
6
Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.使用新型“无框架”宫内左炔诺孕酮释放给药系统治疗月经过多:一项试点研究。
Eur J Contracept Reprod Health Care. 2001 Jun;6(2):93-101.
7
Progestin-releasing intrauterine systems and leiomyoma.释放孕激素的宫内节育系统与平滑肌瘤
Contraception. 2007 Jun;75(6 Suppl):S130-3. doi: 10.1016/j.contraception.2007.01.012. Epub 2007 Mar 9.
8
User satisfaction with a levonorgestrel-releasing intrauterine system (LNG-IUS): data from an international survey.左炔诺孕酮宫内节育系统(LNG-IUS)的用户满意度:一项国际调查的数据
Eur J Contracept Reprod Health Care. 2009 Dec;14(6):391-8. doi: 10.3109/13625180903203154.
9
Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview.左炔诺孕酮释放激素系统(LNG-IUS)的非避孕用途——一项系统的调查与综述
Eur J Obstet Gynecol Reprod Biol. 2006 Mar 1;125(1):9-28. doi: 10.1016/j.ejogrb.2005.10.029. Epub 2005 Dec 1.
10
Therapeutic use of the LNG IUS, and counseling.左炔诺孕酮宫内缓释系统的治疗用途及咨询
Semin Reprod Med. 2001 Dec;19(4):365-72. doi: 10.1055/s-2001-18644.

引用本文的文献

1
Estimating the effect of hormonal contraceptive use on anemia: A cross-sectional comparative analysis of 46 Demographic and Health Surveys.评估激素避孕法的使用对贫血的影响:对46项人口与健康调查的横断面比较分析。
PLoS One. 2025 Jul 16;20(7):e0327083. doi: 10.1371/journal.pone.0327083. eCollection 2025.
2
Suture Fixation of Levonorgestrel-Releasing Device Using the Hysteroscopic Surgery System.使用宫腔镜手术系统对左炔诺孕酮释放装置进行缝合固定
JSLS. 2025 Apr-Jun;29(2). doi: 10.4293/JSLS.2024.00076. Epub 2025 Apr 29.
3
Contraception use and changes in young women with newly diagnosed breast cancer.
新诊断乳腺癌年轻女性的避孕措施使用情况及变化
Fertil Steril. 2025 Mar;123(3):488-498. doi: 10.1016/j.fertnstert.2024.09.024. Epub 2024 Sep 19.
4
Long-term efficacy and safety of levonorgestrel releasing intrauterine system in the treatment of adenomyosis: evidence mapping.左炔诺孕酮宫内缓释系统治疗子宫腺肌病的长期疗效和安全性:证据图谱。
Arch Gynecol Obstet. 2024 Jul;310(1):55-67. doi: 10.1007/s00404-024-07546-7. Epub 2024 Jun 5.
5
What Have We Learned? Implementation of a Shared Learning Agenda and Access Strategy for the Hormonal Intrauterine Device.我们学到了什么?激素宫内节育器共享学习议程和获取策略的实施。
Glob Health Sci Pract. 2022 Oct 31;10(5). doi: 10.9745/GHSP-D-21-00789.
6
Utility of the Levonorgestrel-Releasing Intrauterine System in the Treatment of Abnormal Uterine Bleeding and Dysmenorrhea: A Narrative Review.左炔诺孕酮宫内节育系统在治疗异常子宫出血和痛经中的应用:一项叙述性综述。
J Clin Med. 2022 Oct 1;11(19):5836. doi: 10.3390/jcm11195836.
7
Levonorgestrel-Releasing Intrauterine System Improves Menorrhagia-Related Quality of Life in Patients with Symptomatic Adenomyosis.左炔诺孕酮宫内节育系统改善有症状子宫腺肌病患者月经过多相关的生活质量。
Reprod Sci. 2023 Mar;30(3):966-973. doi: 10.1007/s43032-022-01077-9. Epub 2022 Sep 7.
8
How adenomyosis changes throughout pregnancy: A retrospective cohort study.子宫腺肌病在整个孕期的变化:一项回顾性队列研究。
Int J Gynaecol Obstet. 2023 Mar;160(3):856-863. doi: 10.1002/ijgo.14383. Epub 2022 Aug 17.
9
Observational study of feasibility and acceptability of the levonorgestrel-releasing intrauterine device as a long-acting reversible contraceptive in a primary care setting in India.在印度基层医疗环境中,左炔诺孕酮宫内节育器作为长效可逆避孕方法的可行性和可接受性的观察性研究。
Contracept X. 2022 Jun 30;4:100079. doi: 10.1016/j.conx.2022.100079. eCollection 2022.
10
Effect of Hysteroscopic Polypectomy Combined with Mirena Placement on Postoperative Adverse Reactions and Recurrence Rate of Endometrial Polyps: Based on a Large-Sample, Single-Center, Retrospective Cohort Study.宫腔镜息肉切除术联合放置 Mirena 对子宫内膜息肉术后不良反应和复发率的影响:基于大样本、单中心、回顾性队列研究。
Biomed Res Int. 2022 Apr 26;2022:1232495. doi: 10.1155/2022/1232495. eCollection 2022.